Article
Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Nature communications - 7 Apr 2023
Ter Brugge Petra, Moser Sarah C, Bièche Ivan, Kristel Petra, Ibadioune Sabrina, Eeckhoutte Alexandre, de Bruijn Roebi, van der Burg Eline, Lutz Catrin, Annunziato Stefano, de Ruiter Julian, Masliah Planchon Julien, Vacher Sophie, Courtois Laura, El-Botty Rania, Dahmani Ahmed, Montaudon Elodie, Morisset Ludivine, Sourd Laura, Huguet Léa, Derrien Heloise, Nemati Fariba, Chateau-Joubert Sophie, Larcher Thibaut, Salomon Anne, Decaudin Didier, Reyal Fabien, Coussy Florence, Popova Tatiana, Wesseling Jelle, Stern Marc-Henri, Jonkers Jos, Marangoni Elisabetta
Abstract excerpt
The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods to identify HRD are controversial and there is a medical need for predictive biomarkers. We assess the in vivo response to platinum agents in 55 patient-derived xenografts (PDX) of TNBC to identify determinants of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.